SRR2778056
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.400
- ANGIOGENESIS+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- APICAL_SURFACE+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- COAGULATION+0.300
- COMPLEMENT+0.300
Top 10 suppressed
- MYC_TARGETS_V1-0.400
- PROTEIN_SECRETION-0.400
- TGF_BETA_SIGNALING-0.400
- MYC_TARGETS_V2-0.300
- UV_RESPONSE_DN-0.300
- DNA_REPAIR-0.200
- MITOTIC_SPINDLE-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- ANDROGEN_RESPONSE-0.100
- G2M_CHECKPOINT-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 23849071-df2e-4421-b91d-90f66ec2c162 | — | — | 0.898 |
| 2 | 22f63ce0-5364-48b0-b424-5b971a1dcd33 | — | — | 0.890 |
| 3 | R107 | — | — | 0.868 |
| 4 | SRR3147742 | — | — | 0.862 |
| 5 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.862 |
| 6 | MDT-AP-2584 | Med | Medulloblastoma | 0.852 |
| 7 | BS_S9929Z8B | Ganglioglioma | — | 0.848 |
| 8 | SRR2774182 | — | — | 0.844 |
| 9 | TCGA-LD-A9QF-01A-32R-A41B-07 | — | D | 0.843 |
| 10 | TCGA-A2-A0T1-01A-21R-A084-07 | — | D | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |